Our Insights Oncology Anthony Iannacci 10/6/26 Oncology Anthony Iannacci 10/6/26 Zegfrovy Has Proven Itself to Be a Viable Alternative to Rybrevant + Chemotherapy in 1L EGFR EXON 20 Insertion-Mutated NSCLC Read More Oncology Anthony Iannacci 9/15/26 Oncology Anthony Iannacci 9/15/26 BMS gains approval for first ever CELMoD, Zenbexus, in relapsed/refractory multiple myeloma and appears poised for the approval of one more Read More Chronic Disease Anthony Iannacci 9/2/26 Chronic Disease Anthony Iannacci 9/2/26 Cytokinetics’ Myqorzo is On Track For a Significant Label Expansion into nHCM, Where In-Class Rival Camzyos Failed. Payers are the Next Challenge. Read More Oncology Anthony Iannacci 8/18/26 Oncology Anthony Iannacci 8/18/26 Rigel’s Veppanu scores its first nod in HER2-, ER+, ESR1-mutant locally-advanced or metastatic breast cancer, making it the first PROTAC approved Read More Chronic Disease Anthony Iannacci 7/28/26 Chronic Disease Anthony Iannacci 7/28/26 Lipfendra Brings PCSK9i Efficacy with Oral Convenience Read More Oncology Anthony Iannacci 7/14/26 Oncology Anthony Iannacci 7/14/26 Cogent’s bezuclastinib reduces risk of disease progression or death by 50% in 2L metastatic GIST when combined with standard of care Read More Oncology Anthony Iannacci 7/1/26 Oncology Anthony Iannacci 7/1/26 TROP2 ADCs: A Major Innovation for 1L TNBC Read More Oncology Anthony Iannacci 6/11/26 Oncology Anthony Iannacci 6/11/26 TP53, the most altered gene in oncology Read More Oncology Anthony Iannacci 4/7/26 Oncology Anthony Iannacci 4/7/26 Lifyorli Approved in Platinum-Resistant Ovarian Cancer Thanks to a 35% Reduction in Mortality Read More Chronic Disease Anthony Iannacci 3/31/26 Chronic Disease Anthony Iannacci 3/31/26 Oveporexton Could be a Game-changer for Narcolepsy Type 1 Read More R&D Insights Anthony Iannacci 3/4/26 R&D Insights Anthony Iannacci 3/4/26 The Problem with Primary Market Research Read More Chronic Disease Anthony Iannacci 2/17/26 Chronic Disease Anthony Iannacci 2/17/26 Gene Therapies for Sickle Cell Disease: Expensive but Worth It Read More Oncology Anthony Iannacci 2/13/26 Oncology Anthony Iannacci 2/13/26 Keytruda Grabs its 42nd Approval in PD-L1+ PROC Read More R&D Insights Anthony Iannacci 2/10/26 R&D Insights Anthony Iannacci 2/10/26 Plan for the Best, Prepare for the Worst - Handling Uncertainty in R&D Read More R&D Insights Anthony Iannacci 1/27/26 R&D Insights Anthony Iannacci 1/27/26 Finding the Best R&D Opportunities Read More Chronic Disease Anthony Iannacci 1/8/26 Chronic Disease Anthony Iannacci 1/8/26 Using Equinox Drivers Charts to Understand Fabhalta's Success in PNH Read More R&D Insights Anthony Iannacci 12/29/25 R&D Insights Anthony Iannacci 12/29/25 Measuring Risk in R&D Read More Oncology, R&D Insights Anthony Iannacci 11/11/25 Oncology, R&D Insights Anthony Iannacci 11/11/25 How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC Read More Oncology, R&D Insights Anthony Iannacci 10/30/25 Oncology, R&D Insights Anthony Iannacci 10/30/25 What indications should we focus on? Read More Chronic Disease Anthony Iannacci 9/16/25 Chronic Disease Anthony Iannacci 9/16/25 Journavx, a vast improvement over opioids in moderate acute pain Read More Older Posts
Oncology Anthony Iannacci 10/6/26 Oncology Anthony Iannacci 10/6/26 Zegfrovy Has Proven Itself to Be a Viable Alternative to Rybrevant + Chemotherapy in 1L EGFR EXON 20 Insertion-Mutated NSCLC Read More
Oncology Anthony Iannacci 9/15/26 Oncology Anthony Iannacci 9/15/26 BMS gains approval for first ever CELMoD, Zenbexus, in relapsed/refractory multiple myeloma and appears poised for the approval of one more Read More
Chronic Disease Anthony Iannacci 9/2/26 Chronic Disease Anthony Iannacci 9/2/26 Cytokinetics’ Myqorzo is On Track For a Significant Label Expansion into nHCM, Where In-Class Rival Camzyos Failed. Payers are the Next Challenge. Read More
Oncology Anthony Iannacci 8/18/26 Oncology Anthony Iannacci 8/18/26 Rigel’s Veppanu scores its first nod in HER2-, ER+, ESR1-mutant locally-advanced or metastatic breast cancer, making it the first PROTAC approved Read More
Chronic Disease Anthony Iannacci 7/28/26 Chronic Disease Anthony Iannacci 7/28/26 Lipfendra Brings PCSK9i Efficacy with Oral Convenience Read More
Oncology Anthony Iannacci 7/14/26 Oncology Anthony Iannacci 7/14/26 Cogent’s bezuclastinib reduces risk of disease progression or death by 50% in 2L metastatic GIST when combined with standard of care Read More
Oncology Anthony Iannacci 7/1/26 Oncology Anthony Iannacci 7/1/26 TROP2 ADCs: A Major Innovation for 1L TNBC Read More
Oncology Anthony Iannacci 6/11/26 Oncology Anthony Iannacci 6/11/26 TP53, the most altered gene in oncology Read More
Oncology Anthony Iannacci 4/7/26 Oncology Anthony Iannacci 4/7/26 Lifyorli Approved in Platinum-Resistant Ovarian Cancer Thanks to a 35% Reduction in Mortality Read More
Chronic Disease Anthony Iannacci 3/31/26 Chronic Disease Anthony Iannacci 3/31/26 Oveporexton Could be a Game-changer for Narcolepsy Type 1 Read More
R&D Insights Anthony Iannacci 3/4/26 R&D Insights Anthony Iannacci 3/4/26 The Problem with Primary Market Research Read More
Chronic Disease Anthony Iannacci 2/17/26 Chronic Disease Anthony Iannacci 2/17/26 Gene Therapies for Sickle Cell Disease: Expensive but Worth It Read More
Oncology Anthony Iannacci 2/13/26 Oncology Anthony Iannacci 2/13/26 Keytruda Grabs its 42nd Approval in PD-L1+ PROC Read More
R&D Insights Anthony Iannacci 2/10/26 R&D Insights Anthony Iannacci 2/10/26 Plan for the Best, Prepare for the Worst - Handling Uncertainty in R&D Read More
R&D Insights Anthony Iannacci 1/27/26 R&D Insights Anthony Iannacci 1/27/26 Finding the Best R&D Opportunities Read More
Chronic Disease Anthony Iannacci 1/8/26 Chronic Disease Anthony Iannacci 1/8/26 Using Equinox Drivers Charts to Understand Fabhalta's Success in PNH Read More
R&D Insights Anthony Iannacci 12/29/25 R&D Insights Anthony Iannacci 12/29/25 Measuring Risk in R&D Read More
Oncology, R&D Insights Anthony Iannacci 11/11/25 Oncology, R&D Insights Anthony Iannacci 11/11/25 How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC Read More
Oncology, R&D Insights Anthony Iannacci 10/30/25 Oncology, R&D Insights Anthony Iannacci 10/30/25 What indications should we focus on? Read More
Chronic Disease Anthony Iannacci 9/16/25 Chronic Disease Anthony Iannacci 9/16/25 Journavx, a vast improvement over opioids in moderate acute pain Read More
